Skip to content
10-Q

Quarterly Report

ADAPTIMMUNE THERAPEUTICS PLC ADAPY

0001558370-25-007571

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 1.59B sh
Shares Diluted Q1 2025 · Mar 31, 2025 1.54B sh
Shares Diluted Q1 2025 · Mar 31, 2024 1.45B sh
Capex Q1 2025 · Mar 31, 2025 $1.2M
Capex Q1 2025 · Mar 31, 2024 $102K
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$66.59M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$31.95M
Long Term Debt Q1 2025 · Mar 31, 2025 $25.41M
Long Term Debt Q1 2025 · Dec 31, 2024 $50.24M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $41.05M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $91.14M
Stockholders Equity Q1 2025 · Mar 31, 2025 −$37.43M
Stockholders Equity Q1 2025 · Dec 31, 2024 $11.85M
Stockholders Equity Q1 2025 · Mar 31, 2024 $24.38M
Stockholders Equity Q1 2025 · Dec 31, 2023 $39.51M
Current Liabilities Q1 2025 · Mar 31, 2025 $51.07M
Current Liabilities Q1 2025 · Dec 31, 2024 $64.53M
Total Liabilities Q1 2025 · Mar 31, 2025 $195.5M
Total Liabilities Q1 2025 · Dec 31, 2024 $234.11M
Current Assets Q1 2025 · Mar 31, 2025 $103M
Current Assets Q1 2025 · Dec 31, 2024 $188.17M
Total Assets Q1 2025 · Mar 31, 2025 $158.07M
Total Assets Q1 2025 · Dec 31, 2024 $245.96M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.03
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.03
Eps Basic Q1 2025 · Mar 31, 2025 −$0.03
Eps Basic Q1 2025 · Mar 31, 2024 −$0.03
Sga Expense Q1 2025 · Mar 31, 2025 $23.28M
Sga Expense Q1 2025 · Mar 31, 2024 $19.73M
Rd Expense Q1 2025 · Mar 31, 2025 $28.86M
Rd Expense Q1 2025 · Mar 31, 2024 $35.21M
Net Income Q1 2025 · Mar 31, 2025 −$47.58M
Net Income Q1 2025 · Mar 31, 2024 −$48.5M
Operating Income Q1 2025 · Mar 31, 2025 −$45.73M
Operating Income Q1 2025 · Mar 31, 2024 −$49.26M
Cost Of Revenue Q1 2025 · Mar 31, 2025 $879K
Revenue Q1 2025 · Mar 31, 2025 $7.29M
Revenue Q1 2025 · Mar 31, 2024 $5.68M